Health-care companies were more or less flat as traders rotated into sectors less sensitive to interest-rate moves.
Danish drug maker Novo Nordisk and Anthropic struck a partnership deal to deploy the Claude AI model with the aim of accelerating the development of new medicines.
British firm Reckitt Benckiser, the maker of Mucinex and Lysol, plans to expand U.S. product development and manufacturing to respond more quickly to shifts in consumer demand.